CTLA4 and hepatocellular carcinoma: Similarly, phase 3 RCT HIMALAYA investigated the dual checkpoint inhibitor approach with durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA4) as the frontline treatment for advanced/metastatic HCC.